High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. 2007

Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling-Loving Hall, Columbus, OH 43210, USA. don.benson@osumc.edu

High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) has improved response rates and survival for patients with multiple myeloma (MM). We report a single-institution experience using two conditioning regimens, busulfan, cyclophosphamide, and etoposide (BCV) or high-dose melphalan (HDM). Between July 1992 and August 2003, 110 patients with MM (median age=56.1) underwent HDC with ASCT using either BCV (n=62) or HDM (n=48) in sequential cohorts as the preparative regimen. Overall response rates, progression-free survival, and median overall survival were similar. BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM.

UI MeSH Term Description Entries
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
June 2018, Blood research,
Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
April 2013, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
July 2003, American journal of hematology,
Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
August 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
September 2019, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
August 2023, Annals of hematology,
Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
January 2024, British journal of haematology,
Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
November 2020, Leukemia & lymphoma,
Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
January 2021, Annals of hematology,
Don M Benson, and Patrick J Elder, and Thomas S Lin, and William Blum, and Sam Penza, and Belinda Avalos, and Edward Copelan, and Sherif S Farag
December 2019, Bone marrow transplantation,
Copied contents to your clipboard!